Growth hormone (GH) receptors in prostate cancer: Gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells

Molecular and Cellular Endocrinology

Volumn 220, Issue 1-2, 2004, Pages 109-123

  Weiss Messer, Esther ^a   Merom, Osnat ^a   Adi, Ayala ^a   Karry, Rachel ^a   Bidosee, Maslama ^a   Ber, Rosalie ^a   Kaploun, Alexander ^a   Stein, Avi ^a   Barkey, Ronnie J ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Androgen receptor; DU145 cells; GH receptors; LNCaP cells; PC3 cells; Prostate cancer; Signal transduction

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; GROWTH HORMONE; GROWTH HORMONE BINDING PROTEIN; GROWTH HORMONE RECEPTOR; JANUS KINASE 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44; SERINE; STAT5A PROTEIN;

ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CARCINOGENESIS; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; EXON; GENE EXPRESSION; GROWTH HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

ANIMALS; CATTLE; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH HORMONE; HUMANS; JANUS KINASE 2; MALE; MILK PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOLECULAR WEIGHT; PHOSPHORYLATION; PHOSPHOTYROSINE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; RECEPTORS, SOMATOTROPIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; SUBSTRATE SPECIFICITY; TESTOSTERONE CONGENERS; TIME FACTORS; TRANS-ACTIVATORS;

EID: 2942596479     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2004.03.004     Document Type: Article

References (70)

1. Amit T., Hacham H., Daily O., Hertz P., Barkey R.J., Hochberg Z. The Hep G2 cell line in the study of growth hormone receptor/binding protein. Mol. Cell. Endocrinol. 101:1994;29-36
2. Amit T., Hochberg Z., Yogev-Falach M., Youdim M.B., Barkey R.J. Shedding of growth hormone-binding protein is inhibited by hydroxamic acid-based protease inhibitors: proposed mechanism of activation of growth hormone-binding protein secretase. J. Endocrinol. 169:2001;397-407
3. Amit T., Bergman T., Dastot F., Youdim M.B.H., Amselem S., Hochberg Z. A membrane-fixed truncated isoform of the human growth hormone receptor. J. Clin. Endocrinol. Metab. 82:1997;3813-3817
4. Argetsinger L.S., Campbell G.S., Yang X., Witthuhn B.A., Silvennoinen O., Ihle J.N., Carter-Su C. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell. 74:1993;237-244
5. Bakin R.E., Gioeli D., Sikes R.A., Bissonette E.A., Weber M.J. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res. 63:2003;1981-1989
6. Ballesteros M., Leung K.C., Ross R.J.M., Iismaa T.P., Ho K.K.Y. Distribution and abundance of messenger ribonucleic acid for growth hormone receptor isoforms in human tissues. J. Clin. Endocrinol. Metab. 85:2000;2865-2871
7. Barnard R., Bundesen P.G., Rylatt D.B., Waters M.J. Monoclonal antibodies to the rabbit liver growth hormone receptor: production and characterization. Endocrinology. 115:1984;1805-1813
8. Barnard R., Bundesen P.G., Rylatt D.B., Waters M.J. Evidence from the use of monoclonal antibody probes for structural heterogeneity of the growth hormone receptor. Biochem. J. 231:1985;459-468
9. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254
10. Campbell G.S., Pang L., Miyasaka T., Saltiel A.R., Carter-Su C. Stimulation by growth hormone of MAP kinase activity in 3T3-F442A fibroblasts. J. Biol. Chem. 267:1992;6074-6080
11. Carter-Su C., Smit L.S. Signaling via JAK tyrosine kinases: growth hormone receptor as a model system. Recent Prog. Horm. Res. 53:1998;61-82
12. Chopin L.K., Veveris-Lowe T.L., Philipps A.F., Herington A.C. Co-expression of GH and GHR isoforms in prostate cancer cell lines. Growth Horm. IGF Res. 12:2002;126-136
13. Costello L.C., Liu Y.Y., Zou J., Franklin R.B. Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone. J. Biol. Chem. 274:1999;17499-17504
14. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., Bartsch G., Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54:1994;5474-5478
15. Culig Z., Bartsch G., Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol. Cell. Endocrinol. 197:2002;231-238
16. Dastot F., Sobrier M.L., Duquesnoy P., Duriez B., Goossens M., Amselem S. Alternatively spliced forms in the cytoplasmic domain of the human growth hormone (GH) receptor regulate its ability to generate a soluble GH-binding protein. Proc. Natl. Acad. Sci. U.S.A. 93:1996;10723-10728
17. Dhanasekaran N., Premkumar R.E. Signaling by dual specificity kinases. Oncogene. 17:1998;1447-1455
18. Dirnhofer S., Berger C., Hermann M., Steiner G., Madersbacher S., Berger P. Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate. 35:1998;212-220
19. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate. 42:2000;150-160
20. Eder I.E., Culig Z., Putz T., Nessler-Menardi C., Bartsch G., Klocker H. Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur. Urol. 40:2001;241-251
21. Friend K.E. Cancer and the potential place for growth hormone receptor antagonist therapy. Growth Horm. IGF Res. 11(Suppl. A):2001;S121-S123
22. Kip1 expression. J. Biol. Chem. 275:2000;24500-24505
23. Hedlund T.E., Miller G.J. A serum-free defined medium capable of supporting growth of four established human prostatic carcinoma cell lines. Prostate. 24:1994;221-228
24. Herington A.C., Ymer S., Stevenson J. Identification and characterization of specific binding proteins for growth hormone in normal human sera. J. Clin. Invest. 77:1986;1817-1823
25. Herrington J., Carter-Su C. Signaling pathways activated by the growth hormone receptor. Trends Endocrinol. Metab. 12:2001;252-257
26. Hobisch A., Culig Z., Radmayr C., Bartsch G., Klocker H., Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res. 55:1995;3068-3072
27. Hocquette J.F., Postel-Vinay M.C., Djiane J., Tar A., Kelly P.A. Human liver growth hormone receptor and plasma binding protein: characterization and partial purification. Endocrinology. 127:1990;1665-1672
28. Hocquette J.F., Postel-Vinay M.C., Kayser C., de Hemptinne B., Amar-Costesec A. The human liver growth hormone receptor. Endocrinology. 125:1989;2167-2174
29. Hodge C., Liao J.F., Stofega M., Guan K.L., Carter-Su C., Schwartz J. Growth hormone stimulates phosphorylation and activation of Elk-1 and expression of c-fos, egr-1, and junB through activation of extracellular signal-regulated kinases 1 and 2. J. Biol. Chem. 273:1998;31327-31336
30. Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., Mirand E.A., Murphy G.P. LNCaP model of human prostatic carcinoma. Cancer Res. 43:1983;1809-1818
31. Hughes J.P., Simpson J.S., Friesen H.G. Analysis of growth hormone and lactogenic binding sites cross-linked to iodinated human growth hormone. Endocrinology. 112:1983;1980-1985
32. Ihle J.N., Kerr I.M. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 11:1995;69-74
33. Ilondo M.M., Vanderschueren-Lodeweyckx M., Courtoy P.J., De Meyts P. Cellular processing of growth hormone in IM-9 cells: evidence for exocytosis of internalized hormone. Endocrinology. 130:1992;2037-2044
34. Kadar T., Redding T.W., Ben-David M., Schally A.V. Receptors for prolactin, somatostatin, and luteinizing hormone-re leasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin. Proc. Natl. Acad. Sci. USA. 85:1997;890-894
35. Kaulsay K.K., Zhu T., Bennett W.F., Lee K.O., Lobie P.E. The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology. 142:2001;767-777
36. Kelly P.A., Djiane J., Postel-Vinay M.C., Edery M. The prolactin/growth hormone receptor family. Endocr. Rev. 12:1991;235-251
37. Kemppainen J.A., Lane M.V., Sar M., Wilson E.M. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J. Biol. Chem. 267:1992;968-974
38. Kisseleva T., Bhattacharya S., Braunstein J., Schindler C.W. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 285:2002;1-24
39. Kolle S., Sinowatz F., Boie G., Temmim-Baker L., Lincoln D. Expression of growth hormone receptor in human prostatic carcinoma and hyperplasia. Int. J Oncol. 14:1999;911-916
40. Leung D.W., Spencer S.A., Cachianes G., Hammonds R.G., Collins C., Henzel W.J., Barnard R., Waters M.J., Wood W.I. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature. 330:1987;537-543
41. Lin J.Q., Adam R.M., Santiestevan E., Freeman M.R. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res. 59:1999;2891-2897
42. Love D.W., Whatmore A.J., Clayton P.E., Silva C.M. Growth hormone stimulation of the mitogen-activated protein kinase pathway is cell type specific. Endocrinology. 139:1998;1965-1971
43. Migliaccio A., Piccolo D., Castoria G., Di Domenico M., Bilancio A., Lombardi M., Gong W., Beato M., Auricchio F. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 17:1998;2008-2018
44. Moilanen A.M., Karvonen U., Poukka H., Janne O.A., Palvimo J.J. Activation of Androgen Receptor Function by a Novel Nuclear Protein Kinase. Mol. Biol. Cell. 9:1998;2527-2543
45. Moller C., Hansson A., Enberg B., Lobie P.E., Norstedt G. Growth hormone (GH) induction of tyrosine phosphorylation and activation of mitogen-activated protein kinases in cells transfected with rat GH receptor cDNA. J. Biol. Chem. 267:1992;23403-23408
46. Nevalainen M.T., Valve E.M., Ingleton P.M., Nurmi M., Martikainen P.M., Harkonen P.L. Prolactin and prolactin receptors are expressed and functioning in human prostate. J. Clin. Invest. 99:1997;618-627
47. Pellegrini S., Dusanter-Fourt I. The structure. Eur. J. Biochem. 248:1997;615-633
48. Peterziel H., Mink S., Schonert A., Becker M., Klocker H., Cato A.C.B. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene. 18:1999;6322-6329
49. Reiter E., Bonnet P., Sente B., Dombrowicz D., De Leval J., Closset J., Hennen G. Growth hormone and prolactin stimulate androgen receptor. Mol. Cell. Endocrinol. 88:1992;77-87
50. Reiter E., Hennuy B., Bruyninx M., Cornet A., Klug M., McNamara M., Closset J., Hennen G. Effects of pituitary hormones on the prostate. Prostate. 38:1999;159-165
51. Reiter E., Kecha O., Hennuy B., Lardinois S., Klug M., Bruyninx M., Closset J., Hennen G. Growth hormone directly affects the function of the different lobes of the rat prostate. Endocrinology. 136:1995;3338-3345
52. Ross R.J.M., Esposito N., Shen X.Y., Von Laue S., Chew S.L., Dobson P.R.M., Postel-Vinay M.C., Finidori J. A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein. Mol. Endocrinol. 11:1997;265-273
53. Roupas P., Herington A.C. Processing of growth hormone by rat adipocytes in primary culture: differentiation between release of intact hormone and degradative processing. Endocrinology. 121:1987;1521-1530
54. Ruan W.F., Powell-Braxton L., Kopchick J.J., Kleinberg D.L. Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology. 140:1999;1984-1989
55. Russell P.J., Bennett S., Stricker P. Growth factor involvement in progression of prostate cancer. Clin. Chem. 44:1998;705-723
56. Sadi M.V., Walsh P.C., Barrack E.R. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer. 67:1991;3057-3064
57. Scatchard G. The attraction of proteins for small molecules and ions. Ann. N.Y. Acad. Sci. 51:1949;660-672
58. Silva C.M., Day R.N., Weber M.J., Thorner M.O. Human growth hormone (GH) receptor is characterized as the 134-kilodalton tyrosine-phosphorylated protein activated by GH treatment in IM-9 cells. Endocrinology. 133:1993;2307-2312
59. Simpson L., Parsons R. PTEN: life as a tumor suppressor. Exp. Cell. Res. 264:2001;29-41
60. Sobrier M.-L., Duquesnoy P., Duriez B., Amselem S., Goossens M. Expression and binding properties of two isoforms of the human growth hormone receptor. FEBS Lett. 319:1993;16-20
61. Stein A., Barak M., Mecz Y., Rubinov R., Lurie A. Serum free total prostatic-specific antigen in prostate cancer patients treated with LH-RH agonists. Eur. Urol. 32:1997;64-68
62. Taplin M.E., Ho S.M. The endocrinology of prostate cancer. J. Clin. Endocrinol. Metab. 86:2001;3467-3477
63. Torring N., Dagnaes-Hansen F., Sorensen B.S., Nexo E., Hynes N.E. ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. Prostate. 56:2003;142-149
64. Touw I.P., De Koning J.P., Ward A.C., Hermans M.H.A. Signaling mechanisms of cytokine receptors and their perturbances in disease. Mol. Cell. Endocrinol. 160:2000;1-9
65. Untergasser G., Rumpold H., Hermann M., Dirnhofer S., Jilg G., Berger P. Proliferative disorders of the aging human prostate: involvement of protein hormones and their receptors. Exp. Gerontol. 34:1999;275-287
66. Van der Kwast T.H., Schalken J., Ruizeveld de Winter J.A., van Vroonhoven C.C., Mulder E., Boersma W., Trapman J. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int. J. Cancer. 48:1991;189-193
67. Vlietstra R.J., van Alewijk D.C., Hermans K.G., van Steenbrugge G.J., Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 58:1998;2720-2723
68. Webber M.M., Bello D., Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. 2. Tumorigenic cell lines. Prostate. 30:1997;58-64
69. Weiss-Messer E., Ber R., Amit T., Barkey R.J. Characterization and regulation of prolactin receptors in MA-10 Leydig cells. Mol. Cell. Endocrinol. 143:1998;53-64
70. Winston L.A., Bertics P.J. Growth hormone stimulates the tyrosine phosphorylation of 42- and 45-kDa ERK-related proteins. J. Biol. Chem. 267:1992;4747-4751